Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

医学 安慰剂 益生菌 内科学 泌尿系统 安慰剂对照研究 抗生素 不利影响 胃肠病学 随机对照试验 临床试验 双盲 微生物学 细菌 病理 生物 替代医学 遗传学
作者
Varsha Gupta,Paola Mastromarino,Ritu Garg
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:78 (5): 1154-1161 被引量:31
标识
DOI:10.1093/cid/ciad766
摘要

Abstract Background Widespread antibiotic resistance has sparked interest in the identification of nonantibiotic strategies, particularly probiotics for the prevention of recurrent urinary tract infections (UTIs). We evaluated the effectiveness of prophylactic probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs. Methods This double-blind, placebo-controlled study enrolled 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatment groups: placebo (G1, oral placebo + vaginal placebo), oral probiotic (G2, oral lactic acid bacteria and bifidobacteria + vaginal placebo), vaginal probiotic (G3, oral placebo + vaginal lactobacilli), and probiotic combination (oral lactic acid bacteria and bifidobacteria + vaginal lactobacilli), for 4 months. Participants were followed up for symptomatic UTIs for 1 year. The primary end points were the number of symptomatic UTIs at 4 months, the proportion of participants with at least 1 symptomatic UTI, and the time to the first symptomatic UTI. Results The incidence of UTI at 4 months in G1, G2, G3, and G4 was 70.4%, 61.3%, 40.9%, and 31.8%, respectively. The mean number of symptomatic UTI recurrences at 4 months was significantly lower (P < .05) in G3 (1.06) and G4 (1.07) compared with G1 (2.1) and G2 (1.63). Further, the time to first symptomatic UTI (days) was significantly longer (P < .05) in G3 (123.8) and G4 (141.8) compared with G1 (69.3) and G2 (71.9). Probiotic supplementations were well tolerated with no serious adverse events. Conclusions Prophylactic supplementation with either vaginal probiotics or in combination with oral probiotics demonstrated effectiveness in preventing recurrent symptomatic UTI episodes. Clinical Trials Registration Registered at Clinical Trials Registry India (CTRI): CTRI/2014/02/004425 (https://ctri.nic.in).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
感性的妙菡应助肖雪依采纳,获得10
1秒前
JamesPei应助咿咿呀呀采纳,获得10
2秒前
3秒前
3秒前
慕慕倾完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
CodeCraft应助毫帛采纳,获得10
6秒前
31V发布了新的文献求助10
6秒前
科研通AI6.4应助炙热冰蓝采纳,获得10
8秒前
忐忑的黄豆完成签到,获得积分10
9秒前
腾腾完成签到,获得积分10
10秒前
10秒前
xiaofei应助宋良友采纳,获得10
10秒前
10秒前
11秒前
雷晨晨完成签到 ,获得积分10
11秒前
小白在努力完成签到,获得积分10
12秒前
13秒前
13秒前
王小帅ok完成签到,获得积分10
15秒前
cat发布了新的文献求助10
16秒前
17秒前
pancakie完成签到,获得积分10
19秒前
20秒前
20秒前
科研通AI6.2应助席冥采纳,获得10
21秒前
小米椒发布了新的文献求助10
23秒前
23秒前
SHun完成签到,获得积分10
23秒前
在水一方应助不安听露采纳,获得10
24秒前
24秒前
脑洞疼应助小兔子滑板车采纳,获得10
24秒前
无花果应助cat采纳,获得10
24秒前
25秒前
pancakie发布了新的文献求助10
25秒前
1325850238发布了新的文献求助10
27秒前
29秒前
2420574910完成签到 ,获得积分10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Applied Min-Max Approach to Missile Guidance and Control 3000
Metallurgy at high pressures and high temperatures 2000
Inorganic Chemistry Eighth Edition 1200
High Pressures-Temperatures Apparatus 1000
Free parameter models in liquid scintillation counting 1000
Standards for Molecular Testing for Red Cell, Platelet, and Neutrophil Antigens, 7th edition 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6318470
求助须知:如何正确求助?哪些是违规求助? 8134749
关于积分的说明 17053041
捐赠科研通 5373387
什么是DOI,文献DOI怎么找? 2852316
邀请新用户注册赠送积分活动 1830173
关于科研通互助平台的介绍 1681813